Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion type Assertion NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_head.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion evidence source_evidence_literature NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion SIO_000772 23313046 NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion wasDerivedFrom befree-2016 NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion wasGeneratedBy ECO_0000203 NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.